These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 21057245)
1. Impact of antidepressant treatment history on clinical outcomes in placebo and medication treatment of major depression. Hunter AM; Cook IA; Leuchter AF J Clin Psychopharmacol; 2010 Dec; 30(6):748-51. PubMed ID: 21057245 [No Abstract] [Full Text] [Related]
2. Brain derived neurotrophic factor gene polymorphism (Val66Met) and short-term antidepressant response in major depressive disorder. Chi MH; Chang HH; Lee SY; Lee IH; Gean PW; Yang YK; Lu RB; Chen PS J Affect Disord; 2010 Nov; 126(3):430-5. PubMed ID: 20674983 [TBL] [Abstract][Full Text] [Related]
3. Venlafaxine: new preparation. Just another antidepressant. Prescrire Int; 1998 Aug; 7(36):112-4. PubMed ID: 10342950 [TBL] [Abstract][Full Text] [Related]
4. A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients. Nemeroff CB; Thase ME; J Psychiatr Res; 2007; 41(3-4):351-9. PubMed ID: 16165158 [TBL] [Abstract][Full Text] [Related]
5. Residual symptoms after remission of major depressive disorder with fluoxetine and risk of relapse. Iovieno N; van Nieuwenhuizen A; Clain A; Baer L; Nierenberg AA Depress Anxiety; 2011 Feb; 28(2):137-44. PubMed ID: 21284066 [TBL] [Abstract][Full Text] [Related]
6. A randomized, double-blind, and placebo-controlled trial of quetiapine augmentation of fluoxetine in major depressive disorder. Garakani A; Martinez JM; Marcus S; Weaver J; Rickels K; Fava M; Hirschowitz J Int Clin Psychopharmacol; 2008 Sep; 23(5):269-75. PubMed ID: 18703936 [TBL] [Abstract][Full Text] [Related]
7. Double-blind randomized parallel-group clinical trial of efficacy of the combination fluoxetine plus modafinil versus fluoxetine plus placebo in the treatment of major depression. Abolfazli R; Hosseini M; Ghanizadeh A; Ghaleiha A; Tabrizi M; Raznahan M; Golalizadeh M; Akhondzadeh S Depress Anxiety; 2011 Apr; 28(4):297-302. PubMed ID: 21456039 [TBL] [Abstract][Full Text] [Related]
8. Antidepressant efficacy of venlafaxine. Golden RN; Nicholas L Depress Anxiety; 2000; 12 Suppl 1():45-9. PubMed ID: 11098413 [TBL] [Abstract][Full Text] [Related]
9. Eight-week, placebo-controlled, double-blind comparison of the antidepressant efficacy and tolerability of bupropion XR and venlafaxine XR. Hewett K; Chrzanowski W; Schmitz M; Savela A; Milanova V; Gee M; Krishen A; Millen L; Leary MO; Modell J J Psychopharmacol; 2009 Jul; 23(5):531-8. PubMed ID: 18635695 [TBL] [Abstract][Full Text] [Related]
10. Fluoxetine versus trimipramine in the treatment of depression in geriatric patients. Wehmeier PM; Kluge M; Maras A; Riemann D; Berger M; Kohnen R; Dittmann RW; Gattaz WF Pharmacopsychiatry; 2005 Jan; 38(1):13-6. PubMed ID: 15706460 [TBL] [Abstract][Full Text] [Related]
11. Early improvements in anxiety, depression, and anger/hostility symptoms and response to antidepressant treatment. Farabaugh A; Sonawalla S; Johnson DP; Witte J; Papakostas GI; Goodness T; Clain A; Baer L; Mischoulon D; Fava M; Harley R Ann Clin Psychiatry; 2010 Aug; 22(3):166-71. PubMed ID: 20680189 [TBL] [Abstract][Full Text] [Related]
12. Comparisons of the efficacy and tolerability of extended-release venlafaxine, mirtazapine, and paroxetine in treatment-resistant depression: a double-blind, randomized pilot study in a Chinese population. Fang Y; Yuan C; Xu Y; Chen J; Wu Z; Cao L; Yi Z; Hong W; Wang Y; Jiang K; Gao K; Cui X; Nierenberg AA; J Clin Psychopharmacol; 2010 Aug; 30(4):357-64. PubMed ID: 20571433 [TBL] [Abstract][Full Text] [Related]
13. Comparison study of venlafaxine and paroxetine for the treatment of depression in elderly Chinese inpatients. Hwang JP; Yang CH; Tsai SJ Int J Geriatr Psychiatry; 2004 Feb; 19(2):189-90. PubMed ID: 14758586 [No Abstract] [Full Text] [Related]
14. Preliminary randomized double-blind placebo-controlled trial of tryptophan combined with fluoxetine to treat major depressive disorder: antidepressant and hypnotic effects. Levitan RD; Shen JH; Jindal R; Driver HS; Kennedy SH; Shapiro CM J Psychiatry Neurosci; 2000 Sep; 25(4):337-46. PubMed ID: 11022398 [TBL] [Abstract][Full Text] [Related]
15. The role of IL-12 and TGF-beta1 in the pathophysiology of major depressive disorder. Lee KM; Kim YK Int Immunopharmacol; 2006 Aug; 6(8):1298-304. PubMed ID: 16782542 [TBL] [Abstract][Full Text] [Related]
17. Low frequency (1-Hz), right prefrontal repetitive transcranial magnetic stimulation (rTMS) compared with venlafaxine ER in the treatment of resistant depression: a double-blind, single-centre, randomized study. Bares M; Kopecek M; Novak T; Stopkova P; Sos P; Kozeny J; Brunovsky M; Höschl C J Affect Disord; 2009 Nov; 118(1-3):94-100. PubMed ID: 19249105 [TBL] [Abstract][Full Text] [Related]
18. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. Fruehwald S; Gatterbauer E; Rehak P; Baumhackl U J Neurol; 2003 Mar; 250(3):347-51. PubMed ID: 12638027 [TBL] [Abstract][Full Text] [Related]
19. Efficacy of open-label venlafaxine in subjects with major depressive disorder: associations with neuroendocrine response to serotonergic and noradrenergic probes. Grossman R; Reynolds D; Goodman M; New A; Silverman J; Schmeidler J; Mitropoulou V; Siever LJ Psychiatry Res; 2004 Sep; 128(2):203-6. PubMed ID: 15488964 [TBL] [Abstract][Full Text] [Related]
20. A randomized double-blind clinical trial on analgesic efficacy of fluoxetine for persistent somatoform pain disorder. Luo YL; Zhang MY; Wu WY; Li CB; Lu Z; Li QW Prog Neuropsychopharmacol Biol Psychiatry; 2009 Nov; 33(8):1522-5. PubMed ID: 19733606 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]